Bionik Laboratories Corp.
BNKL
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 501.10K | 575.10K | 486.20K | 242.80K | 191.30K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 501.10K | 575.10K | 486.20K | 242.80K | 191.30K |
| Cost of Revenue | 247.00K | 304.50K | 188.60K | 75.20K | 58.60K |
| Gross Profit | 254.10K | 270.60K | 297.60K | 167.60K | 132.60K |
| SG&A Expenses | 1.29M | 1.22M | 1.18M | 1.16M | 1.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.75M | 1.62M | 1.60M | 1.62M | 1.59M |
| Operating Income | -1.25M | -1.04M | -1.11M | -1.37M | -1.40M |
| Income Before Tax | -1.36M | -1.08M | -1.13M | -1.38M | -1.71M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.36M | -1.08M | -1.13M | -1.38M | -1.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.36M | -1.08M | -1.13M | -1.38M | -1.71M |
| EBIT | -1.25M | -1.04M | -1.11M | -1.37M | -1.40M |
| EBITDA | -1.23M | -1.02M | -1.10M | -1.36M | -1.39M |
| EPS Basic | -0.19 | -0.16 | -0.16 | -0.20 | -0.29 |
| Normalized Basic EPS | -0.12 | -0.10 | -0.10 | -0.13 | -0.18 |
| EPS Diluted | -0.19 | -0.16 | -0.16 | -0.20 | -0.29 |
| Normalized Diluted EPS | -0.12 | -0.10 | -0.10 | -0.13 | -0.18 |
| Average Basic Shares Outstanding | 6.98M | 6.88M | 6.88M | 6.88M | 5.85M |
| Average Diluted Shares Outstanding | 6.98M | 6.88M | 6.88M | 6.88M | 5.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |